Solving the Growing Incidence of Mental Health Conditions

Through clinical trials of psychedelic inspired medicines and therapies

MindMed Clinical Trials

We are researching & developing a broad range of compounds, with the goal of unlocking new pathways for patients to experience sustained mental healing.

Our Philosophy

Overcome

We focus on helping patients overcome rather than survive

We believe patients deserve better than to linger in symptom management forever. We help patients make breakthroughs that get them out of the symptom management cycle that’s all too commonplace in mental healthcare.

Community

We’re building a community with high standards of efficacy and compassion

Effective mental healthcare requires a coordinated effort from therapists, drug developers, and patients. We need shared data to drive insights and better treatment, so we’re working to build that community through partnerships and programs. We hold ourselves and our partners to the highest standards of efficacy and compassion so that we can progress the industry — and patient outcomes — faster.

Toolset

Next-Gen R&D

Developing best-in-class mental health care means more than clinical testing. In addition to conducting trials for the compounds we’re bringing to market, we’re also focused on next-gen research & development, comprehensive treatment programs and integrated toolsets that empower therapists to focus on what they do best.

People

We have the right people for the right reasons

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

JR Rahn Portrait

JR Rahn

Co-Founder, Board Director & Co-CEO

Stephen L. Hurst, JD Portrait

Stephen L. Hurst, JD

Co-Founder, Executive Chair of the Board & Co-CEO

Leonard Latchman Portrait

Leonard Latchman

Co-founder

Dr. Miri Halperin Wernli Portrait

Dr. Miri Halperin Wernli

President; Board Director; Chair of Technology Evaluation, Acquisition and Scientific Integrity Board Committee

Carol Nast Portrait

Carol Nast

Chief Operating Officer

Donald Gehlert, PhD Portrait

Donald Gehlert, PhD

Chief Scientific Officer

Dave Guebert Portrait

Dave Guebert

Chief Financial Officer

Jeanne Bonelle Portrait

Jeanne Bonelle

EVP, Technical Operations

Shahera St. John Portrait

Shahera St. John

VP, Programs

Nico Forte Portrait

Nico Forte

Senior Director, Business Operations and Development

Carole Abel Portrait

Carole Abel

Senior Director Clinical Operations & Program Leader LSD

Madeline Feldman Portrait

Madeline Feldman

Director of Operations & Administration

Collin Gage Portrait

Collin Gage

Head of Corporate Development

Rachann McKnight Portrait

Rachann McKnight

Director, Business Process

Jon Polaha Portrait

Jon Polaha

Financial Analyst

Stanley D. Glick, PhD, MD Portrait

Stanley D. Glick, PhD, MD

Board Director and Chair Scientific Advisory Board

Natalie Wheeler, PhD Portrait

Natalie Wheeler, PhD

Medical Science Liaison with Dova Pharmaceuticals

Matthew W. Johnson, Ph.D Portrait

Matthew W. Johnson, Ph.D

Clinical Advisor

Kenneth Alper, MD Portrait

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine

Dr. Peter Gasser Portrait

Dr. Peter Gasser

Clinical Advisor

Professor Dr. Matthias Liechti, PhD & M.D. Portrait

Professor Dr. Matthias Liechti, PhD & M.D.

Scientific Collaborator & Advisor

Dr. Kim Kuypers Portrait

Dr. Kim Kuypers

Scientific Collaborator & Advisor

Sarah McCallum, PhD Portrait

Sarah McCallum, PhD

Associate Professor of Neuroscience and Experimental Therapeutics (DNET) at Albany Medical College

John Rotrosen, MD Portrait

John Rotrosen, MD

Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry

Brigid Makes Portrait

Brigid Makes

Board Director, Chair of Audit Commitee, Member of Compensation, Nomination and Governance Committee

Perry Dellelce Portrait

Perry Dellelce

Board Director, Member of Audit and Compensation, Nomination and Governance Committees

Bruce Linton Portrait

Bruce Linton

Board Director, Chair of Compensation, Nomination and Governance Committee, Member of Audit Committee

Scott Freeman, MD Portrait

Scott Freeman, MD

Co-Founder & Clinical Advisor

Here to Stay

We’re built for operational agility and a long-run business model

This is a rapidly evolving space; we’re committed to building a business that becomes a long-lasting institution in effective mental health treatment — not a flash-in-the-pan startup that’s here today and gone tomorrow.

Patients-first

We’re a new kind of pharma company

We believe that, as a society, we’re at the start of a paradigm shift in mental health. We want to lead the way in doing it right. That means we’re community-focused, honest, and transparent. Together we can improve our collective mental health.

Quotation Marks

This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”

Kevin O'Leary headshot
Kevin O'Leary Venture Capital Investor

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

 headshot

MindMed named one of 36 startups that could change the world

 headshot